Blog
Archives: FAQs
-
How does a civil action under 35 U.S.C. 145 differ from a direct appeal to the Federal Circuit?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does the 35 U.S.C. 121 prohibition affect statutory double patenting rejections?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
Does the 35 U.S.C. 121 safe harbor protection apply to all types of continuing applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
How does 35 U.S.C. 121 relate to restriction requirements in patent applications?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What does 35 U.S.C. 121 say about patent validity and restriction requirements?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What protection does 35 U.S.C. 121 provide to patent holders regarding improper joinder?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the purpose of 35 U.S.C. 121 in relation to double patenting?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the significance of the 30-month time limit for national stage entry?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What are the implications of the 2007 USPTO policy change for pending applications with multiple nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
-
What is the difference between the 1996 and 2007 USPTO policies on nucleotide sequences?
This page is an FAQ based on guidance from the Manual of Patent Examining Procedure. It is provided as guidance, with links to the ground truth sources. This…
Thirty minutes. Chief IP Officer on retainer — and the capital option behind it.
If what you need is something else, we’ll tell you on the same call.